Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02372409 · ClinicalTrials.gov registry record · Phase 2
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02372409: Clinical Trial Phase 2 study, sponsored by Washington University School of Medicine.
NCT02372409 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02372409, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics whereby the investigators can measure and identify the window of maximal BBB disruption post MLA to 1) allow for an alternative to surgery in incompletely resected tumors, 2) allow for optimal chemotherapeutic dosing to achieve the greatest benefits and the least systemic side effects and 3) distinguish subsequent tumor progression from long-term MLA treatment effects. Preliminary data in adult imaging studies have shown that the BBB disruption lasts for several weeks following treatment before returning to a low baseline. This pilot therapeutic study will provide preliminary validation in pediatric patients.
Primary Outcome
PFS is followed from start of treatment to time of progression or death, whichever occurs first.
Interventions
- DRUG Doxorubicin
- DRUG Etoposide
- DEVICE MRI-guided laser ablation
- DEVICE Dynamic contrast-enhanced (DCE) MRI
- DEVICE Dynamic susceptibility contrast (DSC) MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-08-14 |
| Est. Completion | 2023-03-23 |
| Phase | Phase 2 |
Why NCT02372409 stopped before completion
NCT02372409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT02372409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02372409 about?
NCT02372409 is a clinical study titled "Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors". By employing a combination of advanced MRI techniques and correlative serum biomarkers of blood brain barrier (BBB) disruption, the investigators plan to develop a powerful, first of its kind clinical algorithm in pediatrics whereby the investigators can measure and identify the window of maximal BB...
What is the current status of trial NCT02372409?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2015-08-14. Estimated completion is 2023-03-23.
What interventions are being tested in trial NCT02372409?
The interventions under investigation include: Doxorubicin (DRUG), Etoposide (DRUG), MRI-guided laser ablation (DEVICE), Dynamic contrast-enhanced (DCE) MRI (DEVICE), Dynamic susceptibility contrast (DSC) MRI (DEVICE).
Who is sponsoring clinical trial NCT02372409?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02372409's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI